Company: DMAC
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001437749-25-016488
Chunk: 1

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
armaceutical company committed to improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). DiaMedica’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein, an established therapeutic modality in Asia for the treatment of preeclampsia, acute ischemic stroke and other vascular diseases. Our common shares are publicly traded on The Nasdaq Capital Market under the symbol “ DMAC.”